5-(1-(1-methyl-1H-benzo[d]imidazol-2-yl)ethoxy)-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Catalog No.: 
ACAASQ212
CAS No.: 
-
Molecular Formula: 
C24H22N4O5
Molecular Weight: 
446.46
5-(1-(1-methyl-1H-benzo[d]imidazol-2-yl)ethoxy)-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$830.00InquiryInquiry
250mg95%$1659.00InquiryInquiry
1g95%$4974.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-(1-(1-methyl-1H-benzo[d]imidazol-2-yl)ethoxy)-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
IUPAC Name5-(1-(1-methyl-1H-benzo[d]imidazol-2-yl)ethoxy)-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
Molecular FormulaC24H22N4O5
Molecular Weight446.46
SMILESCC(OC1=CC=C2C(=O)N(C3CCC(=O)N(C)C3=O)C(=O)C2=C1)C1=NC2=CC=CC=C2N1C
InChI KeyACNLIQFWMUMHRZ-UHFFFAOYSA-N

Synthetic Route by SureRoute

1. ACAASQ212 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACIGCS205 route compound structure diagram
    ACIGCS2053319-28-6 In Stock
  2. Plus
  3. ACMKGP740 route compound structure diagram
    ACMKGP7402589697-74-3 In Stock
  4. Then
  5. ACAASQ212 route product structure diagram
    ACAASQ212-
Inquiry

2. ACAASQ212 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACMKGP740 route compound structure diagram
    ACMKGP7402589697-74-3 In Stock
  4. Then
  5. ACAASQ212 route product structure diagram
    ACAASQ212-
Inquiry

3. ACAASQ212 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEEVW616 route compound structure diagram
    ACEEVW616-
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACAASQ212 route product structure diagram
    ACAASQ212-
Inquiry

Comments (0)